NeoGenomics (STU:NG9) Accounts Payable & Accrued Expense : €33.6 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is NeoGenomics Accounts Payable & Accrued Expense?

NeoGenomics's quarterly accounts payable & accrued expense declined from Sep. 2023 (€33.3 Mil) to Dec. 2023 (€32.5 Mil) but then increased from Dec. 2023 (€32.5 Mil) to Mar. 2024 (€33.6 Mil).

NeoGenomics's annual accounts payable & accrued expense increased from Dec. 2021 (€31.6 Mil) to Dec. 2022 (€33.6 Mil) but then declined from Dec. 2022 (€33.6 Mil) to Dec. 2023 (€32.5 Mil).

NeoGenomics Accounts Payable & Accrued Expense Historical Data

The historical data trend for NeoGenomics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics Accounts Payable & Accrued Expense Chart

NeoGenomics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

24.40

30.10

31.61

33.59

32.47

NeoGenomics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															37.99	33.31	33.26	32.47	33.55

NeoGenomics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

NeoGenomics (STU:NG9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (STU:NG9) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

VCYT MYGN TWST OPK LAB CDNA NEOG CSTL FLGT GH TMO DHR A IDXX IQV XSWX:LONN MTD ICLR WAT ILMN

Traded in Other Exchanges

NEO:USA

Address

9490 NeoGenomics Way, Fort Myers, FL, USA, 33912

Website

https://www.neogenomics.com

NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.

NeoGenomics (STU:NG9) Headlines

No Headlines